Following triple treatment, the percentage and absolute number of CXCR3+ tumor-specific CD8+ T cells increased strongly in extratumoral compartments, particularly in blood (Fig. 5a–c, and Supplementary Fig. 9a, b). This evidence concerns the gene CD8A and neoplasm.